Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study
Background Since it was suggested that B cells play a role in the pathogenesis of chronic graft-versus-host disease, rituximab, an anti-CD20 monoclonal antibody targeting B cells, has been shown to be effective in steroid-refractory, chronic graft-versus-host disease. However, most of the data were...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Ferrata Storti Foundation
2010-11-01
|
| Reeks: | Haematologica |
| Online toegang: | https://haematologica.org/article/view/5791 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|
